Autopsy report · NCT00089778

Vaccine Treatment of Kidney Cancer

“fewer tumors than expected expressed FGF-5, led to end of accrual to cohorts A\&B”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 11 months before it stopped.
• 11 participants enrolled.
• Results were posted on the registry 4 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Kidney Cancer

Interventions

117-126:Fibroblast growth factor 5 (FGF-5); Fibroblast growth factor 5 (FGF-5):172-176/217-220; IL-2

Participants

11

Sites

1

Countries

United States

Trials that died the same way

• Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC
  “Early termination was due to insufficient tumor uptake thought to be limited by the binding affinity of EGFR, The termination is not related to any safety or quality concerns.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.